リレー・セラピューティクスに関するコメント

$リレー・セラピューティクス(RLAY.US)$ Check this! Revenue 25.2M, up from 344K YoY! and EPS was -.54 versus estimated was -.83! I Like it. And im watching to see if the market likes it?

QUICK SCALP 18 $RLAY —  STOCK & OPTION PLAY
ALERT ON: $18.07
ON THE ⌚: $18.23
🥇 SIGNED OF MORE UPTREND - $18.36
NEED IT TO BREAK OVER: $18.47
🗝️ indicator for MORE uptrend $18.54
confirmation uptrend - $18.63
mini breakout - $18.88. $リレー・セラピューティクス(RLAY.US)$

$リレー・セラピューティクス(RLAY.US)$ Relay Therapeutics inc. reported the first clinical results of its candidate FGFR2 inhibitor, RLY-4008, Oct. 8, saying it showed "promising early activity" in patients with cholangiocarcinoma FGFR2 fusion, unhindered by the toxicity issues typically associated with FGFR-class drugs.
The study plans to enroll 125 patients with various unresectable or metastatic solid tumors and is evaluating several dose levels of RLY-4008 once or twice a day. As of the September 9 cut-off date for the interim analysis, 48 of 49 participants had primary FGFR2 alterations, the majority of which were fgFR2-fused cholangiocarcinomas.